Novavax COVID-19 Vaccine (Monovalent)
Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older

<table>
<thead>
<tr>
<th>Vaccine Product</th>
<th>Dosage/Injection Amount</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monovalent: Blue capped vial</td>
<td>Primary dose: 5 μg rS and 50 μg of Matrix-M™ adjuvant/0.5 mL</td>
<td>Intramuscular (IM) injection</td>
</tr>
<tr>
<td>Monovalent: Blue capped vial</td>
<td>Booster dose: 5 μg rS and 50 μg of Matrix-M™ adjuvant/0.5 mL</td>
<td>Intramuscular (IM) injection</td>
</tr>
</tbody>
</table>

Note: Use these standing orders in conjunction with Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older

Purpose
To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP).

Policy
Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure
Assess persons 12 years of age and older for vaccination with Novavax COVID-19 Vaccine based on the following criteria:

Persons who are NOT moderately or severely immunocompromised
- If the recipient has never received a COVID-19 vaccine, administer 1 dose of Novavax COVID-19 Vaccine.
- If the recipient has received 1 previous dose of:
  - Novavax COVID-19 Vaccine, administer the second dose at least 3-8 weeks after Dose 1. (Primary series completed)
  - A vaccine product that cannot be determined, is no longer available or contraindicated, administer Novavax COVID-19 Vaccine at least 4-8 weeks after the first dose. (Primary series completed)
- If the recipient has received 2 previous doses of monovalent Novavax COVID-19 Vaccine, administer a bivalent booster dose. See the Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older for guidance
- If the recipient has received a completed primary series of COVID-19 vaccine (Moderna, Pfizer-BioNTech, Novavax or Janssen), administer a single Novavax booster dose at least 6 months after the last primary series dose to persons 18 years of age and older who have not received a previous booster dose(s) in limited situations. These are: an mRNA vaccine contraindicated or not available or the recipient is unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

Additional clinical considerations
- Persons with a history of myocarditis or pericarditis:
  - If history is prior to COVID-19 vaccination, may receive Novavax COVID-19 Vaccine after the episode of myocarditis or pericarditis has completely resolved.
  - If myocarditis or pericarditis occurred after the first dose of an mRNA or Novavax COVID-19 vaccine, generally experts advise no additional doses of any COVID-19 vaccine. Administration of the second dose of an mRNA or Novavax COVID-19 vaccine series can be considered in certain circumstances after the episode of myocarditis or pericarditis has completely resolved. Considerations can be found at Interim Clinical Considerations for COVID-19 vaccination and myocarditis and pericarditis

Persons who ARE moderately or severely immunocompromised
- If the recipient has never received a COVID-19 vaccine, administer 1 dose of Novavax COVID-19 Vaccine.
- If the recipient has received 1 previous dose of:
  - Novavax COVID-19 Vaccine, administer the second dose at least 3 weeks after Dose 1. (Primary series completed)
  - A vaccine product that cannot be determined, is no longer available or contraindicated, administer Novavax COVID-19 Vaccine at least 4 weeks after the first dose. (Primary series completed)
- If the recipient has received 2 previous doses of monovalent Novavax COVID-19 Vaccine, administer a bivalent booster dose. See the Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older for guidance

*† Inform recipients, especially males 12–39 years of age and their parents/legal representative (when relevant) of the possibility of myocarditis or pericarditis following receipt of Novavax COVID-19 vaccines and the need to seek care if symptoms of myocarditis or pericarditis develop after vaccination. Educational materials are available at Clinical Considerations: Myocarditis and Pericarditis after Receipt of mRNA COVID-19 Vaccines Among Adolescents and Young Adults.
†‡ Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).
‡† An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months–6 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. A shorter interval (3 weeks for Novavax) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual’s higher risk of severe disease.
Novavax COVID-19 Vaccine (Monovalent)
Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older

For persons who received COVID-19 vaccine:
- Outside the United States
- Not currently authorized/approved in the United States
- See clinical guidance, including booster dose recommendation, at Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC

Novavax COVID-19 Vaccine may be coadministered with other routinely recommended vaccines without regard to timing, including simultaneous administration.

See clinical guidance for COVID-19 vaccination and SARS CoV-2 infection, including recommendations after receiving passive antibody products, at Clinical Guidance for COVID-19 Vaccination | CDC

Persons who have received HCT or CAR-T-cell therapy
- Revaccinate persons who received doses of COVID-19 vaccine prior to or during HCT or CAR-T-cell therapy with a primary series using monovalent COVID-19 vaccine and 1 booster dose of bivalent COVID-19 vaccine. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.

Screen for contraindications and precautions

Contraindications
History of:
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine
- Known diagnosed allergy to a component of the COVID-19 vaccine. See the EUA fact sheet for a list of vaccine components

Precautions
History of:
- Anaphylaxis after any vaccine other than COVID-19 vaccine or after any injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies [excluding subcutaneous immunotherapy for allergies, i.e., “allergy shots”])
- Non-severe, immediate (onset less than 4 hours) allergic reaction after a dose of one type of COVID-19 vaccine is a precaution to the same type of COVID-19 vaccine
- An allergy-related contraindication to one type of COVID-19 vaccine is a precaution to the other types of COVID-19 vaccines
- Moderate to severe acute illness, with or without fever
- Multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A)
- Myocarditis or pericarditis after a dose of an mRNA or Novavax COVID-19 vaccine

Administration

<table>
<thead>
<tr>
<th>Sex and Weight of Patient</th>
<th>Needle Gauge</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female or male fewer than 130 lbs</td>
<td>22–25</td>
<td>½“ – 1”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female or male 130–152 lbs</td>
<td>22–25</td>
<td>1”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female 152–200 lbs</td>
<td>22–25</td>
<td>1–1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Male 152–260 lbs</td>
<td>22–25</td>
<td>1–1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female 200+ lbs</td>
<td>22–25</td>
<td>1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Male 260+ lbs</td>
<td>22–25</td>
<td>1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
</tbody>
</table>

Provide all recipients with a copy of the current federal Emergency Use Authorization (EUA) Fact Sheet for Recipients and Caregivers.

Prepare to administer the vaccine. Choose the correct needle gauge, needle length, and injection site for persons:
- 12 through 18 years of age:
  » Needle gauge/length: 22-25 gauge, 1-inch
  » Site: Deltoid muscle of arm.
- 19 years of age and older: See chart

Administer Novavax COVID-19 Vaccine by intramuscular injection (IM) injection.
- Primary series dose: 0.5 mL

§ People with a known allergy to polysorbate have a contraindication to both Novavax and Janssen COVID-19 vaccines and a precaution to mRNA COVID-19 vaccines. In all other cases, an allergy-related contraindication to one type of COVID-19 vaccine is a precaution to the other types. Consider consultation with an allergist/immunologist to help determine if a patient with a contraindication to the Novavax vaccine can safely receive another COVID-19 vaccine. Healthcare providers and health departments may also request a consultation from the Clinical Immunization Safety Assessment COVIDvax project. Vaccination of these individuals should only be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions.

¶ Alternatively, the anterolateral thigh can be used. A 1.5-inch needle may be used if administering vaccine in this site.

** Some experts recommend a 5/8-inch needle for men and women who weigh less than 130 pounds. If used, skin must be stretched tightly (do not bunch subcutaneous tissue).
Novavax COVID-19 Vaccine (Monovalent)
Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older

Document vaccination
- COVID-19 vaccination providers must document vaccine administration in their medical record systems within 24 hours of administration and use their best efforts to report administration data to the relevant system (e.g., immunization information system) for the jurisdiction as soon as practicable and no later than 72 hours after administration.
- Document each recipient’s vaccine administration information:
  - Medical record: The vaccine and the date it was administered, manufacturer, lot number, vaccination site and route, name and title of the person administering the vaccine.
  - Recipient’s vaccination record card: Date of vaccination, product name/manufacturer, lot number, and name/location of the administering clinic or healthcare professional.
  - Immunization information system (IIS): Report the vaccination to the appropriate state/local IIS.
- Additional preparation and administration information is available on the manufacturer’s website.

Be prepared to manage medical emergencies
- Vaccination providers should consider observing patients after vaccination to monitor for allergic reactions and syncope:
  - 30 minutes: Persons with a history of:
    - An allergy-related contraindication to a different type of COVID-19 vaccine.
    - A history of non-severe, immediate (onset within 4 hours) allergic reaction after a previous dose of COVID-19 vaccine.
    - A history of anaphylaxis after non-COVID-19 vaccines or injectable therapies.
  - 15 minutes: All other persons
- Syncope may occur in association with injectable vaccines, in particularly among adolescents. Procedures should be in place to avoid falling injuries and manage syncopal reactions.
- Have a written protocol to manage medical emergencies following vaccination, as well as equipment and medications, including at least 3 doses of epinephrine, H1 antihistamine, blood pressure monitor, and timing device to assess pulse.
- Healthcare personnel who are trained and qualified to recognize the signs and symptoms of anaphylaxis as well as administer intramuscular epinephrine should be available at the vaccination location at all times.

Report adverse events to the Vaccine Adverse Event Reporting System (VAERS)
- While this vaccine is under Emergency Use Authorization (EUA), healthcare professionals are required to report to VAERS:
  - Vaccine administration errors (whether associated with an adverse event [AE] or not)
  - Serious AEs (irrespective of attribution to vaccination)
  - Multisystem inflammatory syndrome (MIS) in adults or children
  - Cases of myocarditis (for mRNA and Novavax vaccines)
  - Cases of pericarditis (for mRNA and Novavax vaccines)
  - Cases of COVID-19 that result in hospitalization or death
  - Any additional AEs and revised safety requirements per the Food and Drug Administration’s conditions for use of an authorized vaccine throughout the duration of the EUA
- Healthcare professionals are encouraged to report to VAERS:
  - Clinically important adverse events that occur after vaccination, even if they are not sure whether the vaccine caused the adverse event

For more information, please see:
- CDC’s General Best Practice Guidelines for Immunization, “Preventing and Managing Adverse Reactions,” at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/adverse-reactions.html
- Immunization Action Coalition’s “Medical Management of Vaccine Reactions in Adults in a Community Setting” at https://www.immunize.org/catg.d/p3082.pdf

Note: For more information/guidance, please contact the immunization program at your state or local health department or the appropriate state body (e.g., state board of medical/nursing/pharmacy practice).

Standing Orders Authorization

This policy and procedure shall remain in effect for all patients of the ______________________ effective ______________________ until rescinded or until ______________________.

Medical director (or other authorized practitioner) ______________________ / ______________________ / ______________________

Adapted with appreciation from the Immunization Action Coalition (IAC) standing orders